Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010018352 - HETEROCYCLIC COMPOUNDS USED IN THE TREATMENT OF DISEASES WHERE ENHANCED M3 RECEPTOR ACTIVATION IS IMPLICATED

Publication Number WO/2010/018352
Publication Date 18.02.2010
International Application No. PCT/GB2008/002728
International Filing Date 12.08.2008
IPC
C07D 471/08 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
08Bridged systems
A61K 31/439 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
A61P 11/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
C07D 271/06 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
C07D 271/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
CPC
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
C07D 271/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
C07D 271/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
271Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02not condensed with other rings
101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
C07D 471/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
08Bridged systems
Applicants
  • ARGENTA DISCOVERY LIMITED [GB]/[GB] (AllExceptUS)
  • ASTRAZENECA AB [SE]/[SE] (AllExceptUS)
  • NADIN, Alan, John [GB]/[GB] (UsOnly)
  • OSBOURN, Susan, Elizabeth [GB]/[GB] (UsOnly)
  • TISSELLI, Patrizia [IT]/[GB] (UsOnly)
  • RAY, Nicholas, Charles [GB]/[GB] (UsOnly)
Inventors
  • NADIN, Alan, John
  • OSBOURN, Susan, Elizabeth
  • TISSELLI, Patrizia
  • RAY, Nicholas, Charles
Agents
  • ASTRAZENECA AB
Priority Data
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) HETEROCYCLIC COMPOUNDS USED IN THE TREATMENT OF DISEASES WHERE ENHANCED M3 RECEPTOR ACTIVATION IS IMPLICATED
(FR) COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS DANS LE TRAITEMENT DE MALADIES IMPLIQUANT L’ACTIVATION AMÉLIORÉE DU RÉCEPTEUR M3
Abstract
(EN) The invention provides named compounds of formula (I), pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions and their use in in the treatment of diseases where enhanced M3 receptor activation is implicated.
(FR) La présente invention concerne les composés cités de formule (I), des compositions pharmaceutiques les contenant, un procédé de préparation des compositions pharmaceutiques et leur utilisation dans le traitement de maladies impliquant l’activation améliorée du récepteur M3.
Latest bibliographic data on file with the International Bureau